No. Nasrat put the company in "limp-mode", whereby demands upon him are relatively few.. . . He certainly could do a number of things about any purported manipulation as he has over 300 million shares. As the CEO he could comment upon the stock price through a "letter-to-shareholders" if he weren't a profound example of what is wrong in the pharmaceutical industry today. Nasrat is definitely part of the problem rather than the solution. All of which is somewhat moot as "manipulation" is vastly different than "lack of interest". The latter being something Nasrat must have an acute awareness of vis-a-vis his treatment of both shareholders and his responsibilities as CEO.
News 
Market Data 
Discover 
